Business Wire

Daher and Traxens Signed an Agreement to Supply Customers’ Sensitive Equipement with Smart Monitoring and Tracking Services

Del

Traxens, a company providing high-valued data and services for the supply chain industry, and Daher, a leading logistics and service provider, today announce they have signed a commercial contract to monitor and track the fleet of sensitive equipment of Daher’s customers.

Since 2016, the two companies have been collaborating and they are now entering a long-term contract, after the market revealed high demand for such fleet management solutions in the aerospace and defence industry. This contract with an industrial logistics partner is the first of its kind for Traxens. The roll-out of Traxens devices will take place progressively with Daher’s customers, starting Q4 2018.

As a leading aerospace equipment and service provider, Daher is partner of the world’s biggest programs, hence requires highly trusted monitoring solutions. Daher selected Traxens for its best-in-class solution to secure Daher’s customer supply chain in the aerospace and defense industries. Traxens’ technology will allow Daher to monitor and analyze in real time where and how the goods are advancing through the supply chain process.

“The agreement signed with Daher demonstrates that Traxens is today clearly positioned to become a strategic partner to any company seeking help on regaining control of and value in global supply chains. We are looking forward to this promising partnership,” said Jacques Delort, managing director of Traxens.

Traxens’ technology is capable of gathering and analysing several types of data specific to individual products. The data is transmitted wirelessly from Traxens’ hardware solution, called the Traxens-Box, which, among other features, enables GPS-based product localisation. Customers can then access data through Daher’s cloud platform, named Daher Data Analytics.

“We handle complex full-fledge logistics services for Aerospace OEMs and aircraft manufacturers, relying on our know-how and on advanced technologies,” said Nicolas Orance, Senior Vice President Aerospace and Defense business unit at Daher. “Using Traxens’ reliable and highly-trusted monitoring solution will enable us to strengthen our fleet management services. TRAXENS’ data will be integrated into DAHER Data Analytics platform, to better serve our customers.”

About Daherwww.daher.com

Daher is an aircraft manufacturer and service provider. Daher asserts its expertise in 3 main businesses – aircraft manufacturing, aerospace equipment and systems, logistics and services – and achieved a turnover of 1.1 billion euros in 2017. With the stability provided by its family ownership, Daher has been committed to innovation since its creation in 1863. Today, present in 11 countries, Daher is a leader in the industry 4.0, designing and developing value-added solutions for its industrial partners.

Daher is also on social networks:

Twitter: @DAHER_official
LinkedIn: DAHER
Instagram: DaherTBM
Facebook: @Daherofficial

About TRAXENS www.traxens.com

TRAXENS delivers the world's most extensive, precise and timely information about containers in transit anywhere in the world using breakthrough technology and Big Data techniques. This information provides all stakeholders in multi-modal transport the opportunity to improve costs, optimize investment, and offer premium services.

Contact information

Press:
Géraldine Sauniere
Director of Communications – TRAXENS
g.sauniere@traxens.com
Tel: +33 6 95 91 58 99

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CETPressemelding

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CETPressemelding

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CETPressemelding

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CETPressemelding

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CETPressemelding

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin

Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 16:54:00 CETPressemelding

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.